NCT04128917已完成3 期
A Randomized, Double-Blind, Active-controlled, Multicenter, Pilot Study to Investigate the Safety and Efficacy of a Triple Therapy With Tegoprazan, Amoxicillin and Clarithromycin in H. Pylori Positive Patients
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 102
- 试验地点
- 1
- 主要终点
- H. pylori eradication rate
研究概览
简要总结
This study aims to compare safety and efficacy in an exploratory manner between a Tegoprazan triple therapy and a RAPAE01 triple therapy in H. pylori positive patients.
详细描述
A Randomized, Double-Blind, Active-controlled, Multicenter, Pilot Study to Investigate the Safety and Efficacy of a Tegoprazan triple therapy and a RAPAE01 triple therapy in H. pylori positive patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 19 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •H. pylori positive at screening
- •Subjects who have upper gastrointestinal disease
排除标准
- •Having received prior therapy for eradication of H. pylori
- •Prior use of P-CAB, proton pump inhibitors (PPIs), H2 receptor blockers within 14 days
- •Prior use of H. pylori eradication effective antibiotics, bismuth within 28 days
研究组 & 干预措施
Tegoprazan 50 mg
Experimental
Tegoprazan 50 mg Triple Therapy
干预措施: Tegoprazan (Drug)
Tegoprazan 100 mg
Experimental
Tegoprazan 100 mg Triple Therapy
干预措施: Tegoprazan (Drug)
RAPAE01
Active Comparator
RAPAE01 Triple Therapy
干预措施: RAPAE01 (Drug)
结局指标
主要结局
H. pylori eradication rate
时间窗: Day 49
Assess H. pylori eradication rate by UBT
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
招募中
2 期
Exploratory Study to Standard Triple Therapy With Tegoprazan(by Dose) in H. Pylori Positive PatientsHelicobacter Pylori InfectionNCT05933031HK inno.N Corporation381
已完成
3 期
Triple Therapy With Tegoprazan in H. Pylori Positive PatientsHelicobacter Pylori InfectionNCT03498456HK inno.N Corporation284
已完成
3 期
Study to Confirm the Safety and Efficacy of Tegoprazan in Patients With Healed Erosive EsophagitisHealed Erosive EsophagitisNCT04022096HK inno.N Corporation351
已完成
3 期
Study to Evaluate the Safety, Efficacy of Tegoprazan for the Prevention of PUD in Patients on Treatment With NSAIDsPreventive Peptic UlcerNCT04840550HK inno.N Corporation392
已完成
4 期
Study to Confirm the Safety and Efficacy of Tegoprazan in Patients With Healed Erosive Reflux DiseaseErosive Reflux DiseaseNCT05267743HK inno.N Corporation218